Longevity Next

Intervention

Taurine

Source-reviewed Last reviewed: 2026-10-02

Research Observatory

Evidence Update

Current evidence

Taurine has preclinical intervention signals, including extended mouse lifespan; human aging associations are mixed.

What changed

Adds animal evidence together with distinct human reports and phenotype-dependent observations; participant-level independence is not fully established.

What did not change

No proven human longevity benefit, universal deficiency mechanism or human dose recommendation.

Why it matters

Animal treatment effects and human biomarker patterns answer different causal questions.

Main limitation

Species and exposure differences; human reports are observational and partly abstract-only.

Next proof

Independent replication and controlled human clinical outcomes.

Evidence reviewed through

Evidence release LNPG-REL-20261002-002

Sources

  1. Experimental Evidence Against Taurine Deficiency as a Driver of Aging in Humans.

    Source type primary_research_publication Publication date 2025-08-11

    What this source establishes Compares taurine observations in active and inactive men, adding context to human age associations.

    Important limitation Activity and cohort differences limit inference; observational comparisons cannot establish supplementation benefit.

    Evidence access Relevant full-text sections reviewed.

  2. Is taurine an aging biomarker?

    Source type primary_research_publication Publication date 2025-06-05

    What this source establishes Reports findings inconsistent with a universal age-related decline in circulating taurine.

    Important limitation Age associations do not test whether taurine supplementation benefits humans; review was abstract-level.

    Evidence access Abstract reviewed.

  3. Taurine deficiency as a driver of aging.

    Source type primary_research_publication Publication date 2023-06-09

    What this source establishes Reports preclinical taurine supplementation findings, including mouse lifespan extension.

    Important limitation Animal intervention findings do not establish human lifespan extension or a universal human aging marker.

    Evidence access Abstract and indexed article sections reviewed.

  4. Frailty phenotype reveals heterogeneity in aging and distinct taurine associations.

    Source type primary_research_publication Publication date 2026-02-10

    What this source establishes Reports frailty-specific taurine associations that differ across human subgroups.

    Important limitation Subgroup associations do not establish a universal monotonic aging marker or a causal treatment benefit.

    Evidence access Relevant full-text sections reviewed.

Summary

Taurine has preclinical intervention signals, including extended mouse lifespan; human aging associations are mixed.

Intelligence Take

Animal treatment effects and human biomarker patterns answer different causal questions.

Limitations

Species and exposure differences; human reports are observational and partly abstract-only.

Opens in a new tab